72.19.Z - Other research and experimental development on natural sciences and engineering
20.42.Z - Manufacture of perfumes and toilet preparations
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
63.99.Z - Other information service activities not elsewhere classified
70.22.Z - Business and other management consultancy activities
71.20.A - Food quality testing and analysis
71.20.B - Other technical testing and analysis
72.11.Z - Research and experimental development on biotechnology
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | -57,2 | -37 | -28,7 | 22,6 |
EBITDA | -48,8 | 4,2 | ||
Short time liabilities | 248,4 | 829,2 | ||
Income tax | 0 | 0 | 0 | |
Equity capital | 398,9 | 361,9 | 333,2 | -7,9 |
Operating profit (EBIT) | -53,3 | 6 | ||
Assets | 647,4 | 641 | 642,3 | 0,2 |
Net profit (loss) | -57,2 | -37 | -28,7 | 22,6 |
Cash | 3,3 | 196,2 | ||
Net income from sale | 0 | 0 | ||
Liabilities and provisions for liabilities | 248,4 | 279,1 | 309,1 | 10,7 |
Working assets | 632,9 | 631 | 636,7 | 0,9 |
Basic operational activity income | 0 | 0 | 0 | |
Depreciation | 4,5 | -21,5 | ||
% | % | % | p.p. | |
Profitability of capital | -14,3 | -10,2 | -8,6 | 1,6 |
Equity capital to total assets | 61,6 | 56,5 | 51,9 | -4,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 0 | ||
Current financial liquidity indicator | 2.5473248958587646 | -20,8 | ||
Net dept to EBITDA | 0.06811990588903427 | 3,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane